Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Integrating multisector molecular characterization into personalized peptide vaccine design for patients with newly diagnosed glioblastoma.

ABSTRACT: Integrating multisector molecular characterization into personalized peptide vaccine design for patients with newly diagnosed glioblastoma.

PROVIDER: PRJNA997365 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR25385624_1.fastq.gz	Fastqsanger.gz
	SRR25385624_2.fastq.gz	Fastqsanger.gz
	SRR25385625_1.fastq.gz	Fastqsanger.gz
	SRR25385625_2.fastq.gz	Fastqsanger.gz
	SRR25385626_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 30

Similar Datasets

Personalized NeoAntigen Cancer Vaccine with RT for Newly Diagnosed Glioblastoma

Project description:Personalized NeoAntigen Cancer Vaccine with RT for Newly Diagnosed Glioblastoma

| PRJNA429518 | ENA

Personalized NeoAntigen Cancer Vaccine with RT for Newly Diagnosed Glioblastoma

Project description:Personalized NeoAntigen Cancer Vaccine with RT for Newly Diagnosed Glioblastoma

| PRJNA429519 | ENA

Integrating multisector molecular characterization into personalized peptide vaccine design for patients with newly diagnosed glioblastoma.

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-04-12 | GSE238012 | GEO

Single cell analysis of newly diagnosed AML patients

Project description:Single cell analysis of newly diagnosed AML patients

| PRJNA1000621 | ENA

Single cell analysis of newly diagnosed AML patients

Project description:Acute Myeloid Leukemia (AML) is a heterogenous disease characterized by immature blasts at different maturation stage. We used single cell sequencing technique to analyze newly diagnosed AML patients.

2023-12-18 | GSE239721 | GEO

A Gene Expression-Based Risk Stratification Model for Newly Diagnosed Multiple Myeloma

Project description:We recently defined a gene expression-based signature of high-risk multiple myeloma; this predictive signature was developed with and independently validated for newly diagnosed patients treated with high dose therapy and stem cell rescue. Here we use Phase 3 clinical trial data to show that this signature also predicts short survival in relapsed disease treated with single agent bortezomib or high dose dexamethasone. In addition, a survival signature derived with relapsed myeloma samples identified newly diagnosed patients with short survival. Taken together these data suggest that a similar biology underlies poor outcome in both newly diagnosed and relapsed myeloma and provide strong evidence that the high-risk signature is a powerful tool to identify patients who are candidates for new therapeutic regimens. Keywords: Model validation

2011-08-20 | GSE8991 | GEO

A Gene Expression-Based Risk Stratification Model for Newly Diagnosed Multiple Myeloma

2011-08-19 | E-GEOD-8991 | biostudies-arrayexpress

Differential gene expression profile of newly diagnosed versus relapse acute promyelocytic leukemia

Project description:The aim of this study was to gain insight into the potential mechanism of resistance to arsenic trioxide and to identify genes that are modulated in the malignant promyelocytes at the time of relapse in APL patients. We analyzed the gene expression profile by the whole genome microarray of primary promyelocytes obtained from 8 newly diagnosed and 8 at relapse patients. Agilent one-color experiment,Organism: Human ,Agilent Whole Genome Human 4x44k (AMADID: 014850) , Labeling kit: Agilent Quick-Amp labeling Kit (p/n5190-0442) newly diagnosed versus relapse acute promyelocytic leukemia

2013-08-02 | E-GEOD-42030 | biostudies-arrayexpress

Integrative Analysis of a series of newly diagnosed Diffuse Large B-cell Lymphomas (DLBCLs)

Project description:Diffuse large B-cell lymphoma (DLBCL) is a clinically and biologically heterogeneous disease. We have characterized recurrent copy number alterations (CNAs) in a large series of primary DLBCLs with HD-SNP arrays and the GISTIC algromithm. We evaluated the associations between transcript abundance and the presence of specific CNAs by obtaining RNA profiles on the majority of the primary DLBCLs and integrating the gene expression profiles with the copy number data. High molecular weight DNA and total RNA were extracted from frozen biopsy specimens of newly diagnosed and previously untreated primary DLBCLs according to IRB-approved protocols. DLBCL diagnoses and > 80% tumor involvement were confirmed by expert hematologists. 180 primary DLBCLs and 53 normal DNA samples were profiled on Affymetrix SNP array 6.0. 169 of these primary DLBCLs were RNA profiled, 78 on Affymetrix U133A+B and 91 on U133plus2 arrays.

2012-09-12 | E-GEOD-34171 | biostudies-arrayexpress

Expression data of newly diagnosed multiple myeloma and extramedullary myeloma

Project description:Expression data of newly diagnosed multiple myeloma and extramedullary myeloma

| PRJNA622259 | ENA